Fig. 4: Change in nirsevimab IC50 for major RSV F protein variants evaluated in the Phase 2b and MELODY trials (full cohort). | Nature Communications

Fig. 4: Change in nirsevimab IC50 for major RSV F protein variants evaluated in the Phase 2b and MELODY trials (full cohort).

From: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Fig. 4

Individual major variant substitutions from Phase 2b and MELODY trials were evaluated in a validated RSV neutralization susceptibility assay (Viroclinics Biosciences BV, Rotterdam, NLD) and compared with RSV A and B reference viruses. Both I206M and Q209R were identified in RSV B. Green, yellow and red banding represents a low, medium, and high degree of IC50 fold change, respectively. IC50 half-maximal inhibitory concentration, RSV respiratory syncytial virus.

Back to article page